Valuation : Cadrenal Therapeutics, Inc.

Market Cap 4.28M 3.68M 3.47M 3.16M 5.91M 407M 5.94M 41.11M 15.89M 208M 16.08M 15.73M 657M P/E 2026 *
-0.31x
P/E 2027 * -0.4x
Enterprise Value 4.28M 3.68M 3.47M 3.16M 5.91M 407M 5.94M 41.11M 15.89M 208M 16.08M 15.73M 657M EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
88.07%
Yield 2026 *
-
Yield 2027 * -
08-31 Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of Cad-1005 in Heparin-Induced Thrombocytopenia CI
08-13 Cadrenal Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
08-03 Cadrenal Therapeutics Solidifies Multi-Indication Strategy For CAD-1005 In Cardiac Acute Critical Care CI
07-13 Cadrenal Therapeutics, Inc. Demonstrates Greater Than 25% Reduction in Thrombotic Events with CAD-1005 in Phase 2 Hit Clinical Trial CI
07-10 Cadrenal Therapeutics, Inc. Announces Resignation of James J. Ferguson III from Chief Medical Officer Role, Effective July 31, 2026 CI
07-01 Cadrenal Therapeutics Prices Private Placement for Up to $8.8 Million MT
06-29 Cadrenal Therapeutics, Inc. announced that it expects to receive $3 million in funding CI
06-29 Cadrenal Therapeutics, Inc. Announces CFO Changes CI
06-29 Cadrenal Therapeutics, Inc. Announces Board and Committee Changes CI
06-24 Cadrenal Therapeutics Announces Selection of Cad-1005 Phase 2 Study for Late-Breaking Oral Presentation At Isth Congress CI
06-18 Cadrenal Therapeutics, Inc. Plans To Submit Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease CI
06-18 Cadrenal Therapeutics to Seek US FDA's Rare Pediatric Disease Designation for Tecarfarin to Treat Children With Kawasaki Disease MT
06-15 Cadrenal Therapeutics Advances Multi-Indication Strategy For CAD-1005 And Launches Phase 2a Acute Kidney Injury Clinical Plan CI
1 day-0.42%
1 week-11.65%
Current month-32.86%
1 month-39.43%
3 months-70.25%
6 months-85.31%
Current year-82.67%
1 week 1.14
Extreme 1.14
1.41
1 month 1.14
Extreme 1.14
2.29
Current year 1.14
Extreme 1.14
8.96
1 year 1.14
Extreme 1.14
14.64
3 years 1.14
Extreme 1.14
32.55
5 years 1.14
Extreme 1.14
101.25
10 years 1.14
Extreme 1.14
101.25
Manager TitleAgeSince
Chief Executive Officer 61 2022-01-24
Director of Finance/CFO 61 2026-06-24
Chief Operating Officer 58 2024-02-05
Director TitleAgeSince
Director/Board Member 76 2023-01-18
Director/Board Member 78 2023-01-18
Chairman 61 2022-01-24
Date Insider Type Main position Quantity % Market Cap. Importance
6/2/26 Sell

Chief Executive Officer

-349 0.0122%
5/28/26 Sell

Chief Executive Officer

-2,989 0.1192%
5/22/26 Sell

Chief Executive Officer

-1,165 0.0465%
Change 5-day change 1-year change 3-year change Capi.($)
-0.42%-11.65%-91.02%-91.00% 4.28M
-0.94%+0.31%+40.04%+103.25% 69.19B
-0.07%-3.93%+32.54%+75.96% 62.97B
+3.98%+2.13%-12.14%+388.04% 27.27B
-1.24%-6.08%-4.50%-17.34% 24.78B
-0.93%-1.29%+25.30%+16.70% 25.8B
-1.43%-1.89%+21.32%-17.67% 20.11B
-4.27%+2.67%+219.02%+362.48% 18.47B
-1.43%-1.80%-8.64%+537.09% 14.88B
+0.53%-1.28%+50.94%+162.76% 14.29B
Average -0.62%-2.33%+27.28%+152.03% 27.78B
Weighted average by Cap. -0.49%-0.76%+36.37%+141.01%

Financials

2026 *2027 *
Net sales - -
Net income -12.6M -10.84M -10.21M -9.3M -17.4M -1.2B -17.47M -121M -46.76M -611M -47.31M -46.28M -1.94B -17.2M -14.8M -13.94M -12.7M -23.76M -1.64B -23.85M -165M -63.84M -834M -64.59M -63.18M -2.64B
Net Debt - -
Logo Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. The Company's lead program, CAD-1005, is Phase III ready, being researched as a first-in-class 12-lipoxygenase (12-LOX) inhibitor for treating heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. Second-generation 12-LOX oral therapeutics are also in development for chronic indications. Its pipeline includes tecarfarin, a late-stage Phase III ready oral vitamin K antagonist designed to prevent heart attacks, strokes, and deaths from blood clots in patients requiring chronic anticoagulation, including those with end-stage kidney disease (ESKD) and those with left ventricular assist devices (LVADs), and frunexian, a parenteral Factor XIa inhibitor intended for use in acute hospital settings. The development of tecarfarin is focused on ESKD patients with atrial fibrillation and patients with implanted LVADs.
Employees
-
Date Price Change Volume
26-09-09 US$1.175 -2.08% 74,320
26-09-08 US$1.200 -1.64% 162,008
26-09-04 US$1.220 -4.69% 180,822
26-09-03 US$1.280 -3.76% 172,383
26-09-02 US$1.330 -11.92% 394,388
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
1.200USD
Average target price
14.00USD
Spread / Average Target
+1,066.67%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CVKD Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!